Univariate and multivariable hazard ratios for overall survival and progression-free survival in patients with relapsed non-Hodgkin lymphoma treated with either 131I-tositumomab, etoposide, and CTX or total-body irradiation, etoposide, and CTX
| Survival results/treatment . | Univariate hazard ratio (95% CI) . | Pvalue . | Multivariable hazard ratio5-150 (95% CI) . | P value . |
|---|---|---|---|---|
| OS | ||||
| TBI, etoposide, CTX | 1.0 | — | 1.0 | — |
| 131I-tositumomab, etoposide, CTX | 0.3 (0.1-0.6) | .0007 | 0.3 (0.1-0.7) | .004 |
| PFS | ||||
| TBI, etoposide, CTX | 1.0 | — | 1.0 | — |
| 131I-tositumomab, etoposide, CTX | 0.4 (0.2-0.6) | .0003 | 0.4 (0.2-0.7) | .002 |
| Survival results/treatment . | Univariate hazard ratio (95% CI) . | Pvalue . | Multivariable hazard ratio5-150 (95% CI) . | P value . |
|---|---|---|---|---|
| OS | ||||
| TBI, etoposide, CTX | 1.0 | — | 1.0 | — |
| 131I-tositumomab, etoposide, CTX | 0.3 (0.1-0.6) | .0007 | 0.3 (0.1-0.7) | .004 |
| PFS | ||||
| TBI, etoposide, CTX | 1.0 | — | 1.0 | — |
| 131I-tositumomab, etoposide, CTX | 0.4 (0.2-0.6) | .0003 | 0.4 (0.2-0.7) | .002 |
OS indicates overall survival; PFS, progression-free survival; CTX, cyclophosphamide; TBI, total-body irradiation.
Adjusted for histologic type (aggressive versus indolent NHL), number of previous chemotherapy regimens, sensitivity to chemotherapy at time of transplantation (chemosensitive versus chemoresistant), and tumor bulk.